Scarica l'app Stockscreener
3.9108
2.00%
-0.0892
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$4.00
Aprire:
$4.01
Volume 24 ore:
601.36K
Relative Volume:
0.26
Capitalizzazione di mercato:
$343.59M
Reddito:
$30.91M
Utile/perdita netta:
$-209.47M
Rapporto P/E:
-1.1752
EPS:
-3.3279
Flusso di cassa netto:
$-147.13M
1 W Prestazione:
+2.62%
1M Prestazione:
-9.26%
6M Prestazione:
-54.63%
1 anno Prestazione:
-30.50%
Intervallo 1D:
$3.85
$4.12
Intervallo di 1 settimana:
$3.67
$4.19
Portata 52W:
$3.55
$11.24
Verastem Inc Stock (VSTM) Company Profile
Nome
Verastem Inc
Settore
Industria
Telefono
(781) 292-4200
Indirizzo
117 KENDRICK STREET, NEEDHAM, MA
Compare VSTM vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VSTM
Verastem Inc
|
3.91 | 351.49M | 30.91M | -209.47M | -147.13M | -3.3279 |
VRTX
Vertex Pharmaceuticals Inc
|
449.32 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
613.56 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.10 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
279.06 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.83 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Verastem Inc Stock (VSTM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-12 | Ripresa | BTIG Research | Buy |
| 2026-02-04 | Iniziato | H.C. Wainwright | Buy |
| 2025-10-16 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-04-10 | Iniziato | Jefferies | Buy |
| 2025-03-24 | Reiterato | H.C. Wainwright | Buy |
| 2024-12-31 | Reiterato | BTIG Research | Buy |
| 2024-09-30 | Iniziato | Guggenheim | Buy |
| 2023-11-21 | Ripresa | BTIG Research | Buy |
| 2023-09-27 | Iniziato | B. Riley Securities | Buy |
| 2023-06-15 | Aggiornamento | Mizuho | Neutral → Buy |
| 2022-09-07 | Ripresa | Alliance Global Partners | Buy |
| 2022-04-29 | Ripresa | Cantor Fitzgerald | Overweight |
| 2022-04-14 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-03-09 | Iniziato | Truist | Buy |
| 2021-07-01 | Iniziato | Alliance Global Partners | Buy |
| 2021-05-24 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2019-06-20 | Downgrade | BTIG Research | Buy → Neutral |
| 2019-05-10 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2018-07-13 | Iniziato | BTIG Research | Buy |
| 2018-05-02 | Iniziato | Seaport Global Securities | Buy |
| 2018-03-08 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2017-09-07 | Reiterato | H.C. Wainwright | Buy |
| 2017-04-13 | Iniziato | Oppenheimer | Outperform |
| 2017-03-24 | Reiterato | H.C. Wainwright | Buy |
| 2015-09-29 | Downgrade | Cantor Fitzgerald | Buy → Hold |
| 2015-09-29 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2015-09-29 | Downgrade | Jefferies | Buy → Hold |
| 2015-09-29 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2015-09-28 | Downgrade | Mizuho | Buy → Neutral |
| 2015-09-28 | Downgrade | ROTH Capital | Buy → Neutral |
| 2015-09-09 | Iniziato | Raymond James | Strong Buy |
| 2015-05-12 | Reiterato | UBS | Buy |
| 2015-04-08 | Iniziato | H.C. Wainwright | Buy |
| 2015-01-23 | Reiterato | ROTH Capital | Buy |
| 2014-07-08 | Ripresa | Oppenheimer | Perform |
| 2014-02-11 | Iniziato | Mizuho | Buy |
Mostra tutto
Verastem Inc Borsa (VSTM) Ultime notizie
Early data on new KRAS cancer pill to be detailed June 23 - Stock Titan
Analysts Offer Insights on Healthcare Companies: Verastem (VSTM), Jazz Pharmaceuticals (JAZZ) and Humana (HUM) - The Globe and Mail
Why Did Verastem Stock Jump After-Hours Despite An Earnings Miss? - Stocktwits
VSTM Technical Analysis & Stock Price Forecast - Intellectia AI
Verastem’s VS-7375 receives FDA fast track status for lung cancer - Investing.com UK
Verastem announces FDA Fast Track designation for VS-7375 - TipRanks
Verastem, Inc. receives U.S. FDA fast track for KRAS G12D inhibitor in NSCLC treatment - Traders Union
Verastem (VSTM) Surges 11% Following FDA Fast Track Designation - GuruFocus
Verastem’s VS-7375 receives FDA fast track status for lung cancer By Investing.com - Investing.com South Africa
Verastem (VSTM) Receives Fast Track Designation for Cancer Treat - GuruFocus
Verastem stock rises on FDA fast track for lung cancer drug - Investing.com Canada
Verastem Initiates Phase 2 Target-D 202 Trial For Advanced NSCLC - TradingView
Verastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational KRAS G12D (ON/OFF) Inhibitor for the Treatment of KRAS G12D-Mutated Locally Advanced or Metastatic Non-Small Cell Lung - Business Wire
Verastem Inc stock (US92335V1008): Nasdaq-listed oncology player steadies around late-May levels - AD HOC NEWS
VSTM Stock Price, Quote & Chart | VERASTEM INC (NASDAQ:VSTM) - ChartMill
Mizuho Securities Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $14 - Moomoo
Verastem (VSTM) Declines 2.5% as Biotech Sector Headwinds PersistPullback Trade - thelegaladvocate.com
Verastem (NASDAQ: VSTM) director receives 108,000 restricted stock units - Stock Titan
New Verastem (NASDAQ: VSTM) director files initial Form 3 ownership - Stock Titan
[144] Verastem, Inc. SEC Filing - Stock Titan
Biopharma Verastem Oncology joins Jefferies healthcare fireside chat June 3 - Stock Titan
Verastem Oncology to Present at Jefferies Healthcare Conference - marketscreener.com
Verastem: Robert Gagnon Stepped Down From Board Following End of Term on May 21 >VSTM - Moomoo
H.C. Wainwright Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Director at Verastem (VSTM) receives 36,000 RSUs as equity award - Stock Titan
Director Brian Stuglik (VSTM) awarded 36,000 Verastem RSUs with 2026–2027 vesting - Stock Titan
Verastem (NASDAQ: VSTM) awards 36,000 RSUs to director Rowinsky - Stock Titan
Verastem (VSTM) director Michelle Robertson awarded 36,000 RSUs - Stock Titan
Verastem (VSTM) director Anil Kapur receives 36,000 RSU equity award - Stock Titan
Verastem (VSTM) director awarded 36,000 RSUs vesting through 2027 - Stock Titan
Verastem (VSTM) director gets 36,000 RSU award vesting through 2027 - Stock Titan
Verastem Oncology Appoints Michael P. Bailey to Board of Directo - GuruFocus
Verastem (VSTM) stockholders back board slate, equity plans and auditor at 2026 meeting - Stock Titan
Verastem Oncology appoints Michael Bailey to board By Investing.com - Investing.com Australia
Verastem Oncology appoints Michael Bailey to board - Investing.com
AVEO CEO Michael Bailey joins Verastem board, rare cancer focus - Stock Titan
Verastem Q1 2026 Earnings: Narrower-than-Expected Loss Beats Estimates; Stock Edges HigherEnergy Earnings Report - thelegaladvocate.com
Verastem (VSTM) Q1 2026 Earnings: Why the Beat MattersEarnings Seasonality - thelegaladvocate.com
Verastem Q1 earnings call highlights - MSN
Verastem Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Cancer Stocks That Are Advancing the Future of Oncology Care - TradingView
Verastem (VSTM) Loses 34.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Verastem Q3 2025 Earnings Preview - MSN
Foresite (VSTM) holds 3,146,631 shares, reporting 3.6% stake - Stock Titan
Armistice Capital 5.23% stake in Verastem (VSTM) via managed fund - Stock Titan
RTW Funds, Roderick Wong Report 9.99% of Verastem (VSTM) - Stock Titan
Balyasny-affiliated holders report 1.36M shares in Verastem (VSTM) - Stock Titan
Verastem Oncology announces management changes - MSN
VSTM Maintained by Mizuho -- Price Target Lowered to $14.00 - GuruFocus
MSN Money - MSN
Mizuho Adjusts Price Target on Verastem to $14 From $16, Maintains Outperform Rating - Moomoo
Verastem Inc Azioni (VSTM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.40%
0.80%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):